Journal: Dose-Response

Article Title: TSN Disrupts Fanconi Anemia Pathway Activation Through JAK/STAT1-Mediated Transcriptional Repression of FA Core Subunits in Bladder Cancer

doi: 10.1177/15593258251406039

Figure Lengend Snippet: Toosendanin inhibits JAK/STAT1 pathway. (A-C) Western blot shows the phosphorylation of SMAD2, STAT1 and ERK in bladder cancer T24 (A), RT4 (B) and J82 (C) cell lines induced by UVC and treated with TSN. (D-F) Immunofluorescence shows the nuclear translocation of p-SMAD2 (D), p-STAT1 (E) and p-ERK (F) in bladder cancer T24 cells induced by UVC and treated with TSN. (G-I) Western blot shows the phosphorylation of STAT1 and the expression of FANCA, FANCC, FANCF and FANCM in bladder cancer T24 (G), RT4 (H) and J82 (I) cell lines induced by UVC and treated with TSN, JAK/STAT1 agonist or inhibitor. (J-L) Histogram shows the RNA levels of FANCA, FANCC, FANCF and FANCM in bladder cancer T24 (J), RT4 (K) and J82 (L) cell lines induced by UVC and treated with TSN as well as JAK/STAT1 agonist and inhibitor by qPCR. (M-O) ChIP-qPCR shows the binding capacity of STAT1 on promoters of FANCA, FANCC, FANCF and FANCM in bladder cancer T24 (M), RT4 (N) and J82 (O) cell lines induced by UVC and treated with TSN and JAK/STAT1 agonist. Numerical P -values indicate the statistical significance compared with cells treated with UVC and TSN. Abbreviation: JI, JAK/STAT1 inhibitor Ruxolitinib; JA, JAK/STAT1 agonist IFN-γ

Article Snippet: Cells were incubated with the final concentrations of 100 nM Toosendanin (TSN, purity ≥98%, HY-N0263, MedChemExpress, China) for 24 h, 1 μM JAK/STAT1 inhibitor Ruxolitinib (HY-50856, MedChemExpress) for 24 h, 20 ng/mL JAK/STAT1 agonist interferon-gamma (IFN-γ, HY- P73252 , MedChemExpress) for 1 h.

Techniques: Western Blot, Phospho-proteomics, Immunofluorescence, Translocation Assay, Expressing, ChIP-qPCR, Binding Assay

Journal: Cancer Management and Research

Article Title: Identification of Key Genes and FUNCTIONAL Pathway in Radioresistance of Non-Small Cell Lung Cancer

doi: 10.2147/CMAR.S382079

Figure Lengend Snippet: ChIP-X Enrichment Analysis Results

Article Snippet: Figure 5 Effects of STAT1 inhibitor on radiotherapy resistance. ( A ) The expression levels of total STAT1 and p-STAT1 (Y701). ( B ) Relative expression of STAT1 and p-STAT1. ( C ) Relative expression of PD-L1. ( D ) The expression levels of PD-L1. ( E ) Quantification of PD-L1 expression. ( F ) A549-RR cells were planted and incubated with STAT1 inhibitor (S1491, Selleck, 2μg/mL, 24h) followed by radiotherapy and then cultured for 2 weeks. ( G ) Clone formation rate according to D, the results were calculated according to the ratio of clone number to inoculated cell number. ( H ) Survival fraction according to D. * p < 0.05, ** p < 0.01, *** p < 0.001.

Techniques:

Journal: Cancer Management and Research

Article Title: Identification of Key Genes and FUNCTIONAL Pathway in Radioresistance of Non-Small Cell Lung Cancer

doi: 10.2147/CMAR.S382079

Figure Lengend Snippet: Effects of STAT1 inhibitor on radiotherapy resistance. ( A ) The expression levels of total STAT1 and p-STAT1 (Y701). ( B ) Relative expression of STAT1 and p-STAT1. ( C ) Relative expression of PD-L1. ( D ) The expression levels of PD-L1. ( E ) Quantification of PD-L1 expression. ( F ) A549-RR cells were planted and incubated with STAT1 inhibitor (S1491, Selleck, 2μg/mL, 24h) followed by radiotherapy and then cultured for 2 weeks. ( G ) Clone formation rate according to D, the results were calculated according to the ratio of clone number to inoculated cell number. ( H ) Survival fraction according to D. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: Figure 5 Effects of STAT1 inhibitor on radiotherapy resistance. ( A ) The expression levels of total STAT1 and p-STAT1 (Y701). ( B ) Relative expression of STAT1 and p-STAT1. ( C ) Relative expression of PD-L1. ( D ) The expression levels of PD-L1. ( E ) Quantification of PD-L1 expression. ( F ) A549-RR cells were planted and incubated with STAT1 inhibitor (S1491, Selleck, 2μg/mL, 24h) followed by radiotherapy and then cultured for 2 weeks. ( G ) Clone formation rate according to D, the results were calculated according to the ratio of clone number to inoculated cell number. ( H ) Survival fraction according to D. * p < 0.05, ** p < 0.01, *** p < 0.001.

Techniques: Expressing, Incubation, Cell Culture

Journal:

Article Title: Signaling of short- and long-term regulation of intestinal epithelial type 1 Na + /H + exchanger by interferon- γ

doi: 10.1038/sj.bjp.0706167

Figure Lengend Snippet: Abundance of total STAT1, phospho-STAT1 and phospho-p38 MAPK in Caco-2 cells treated with vehicle and IFN-γ (1000 U ml−1) or anisomycin (100 nM) for 1, 3 and 24 h.

Article Snippet: Total and phosphorylated STAT1 protein levels in Caco-2 cells exposed to IFN- γ (1000 U ml −1 ) and anisomycin (100 n M ) for 1, 3 and 24 h were analyzed using the PhosphoPlus® Stat1 (Tyr701) antibody kit (Cell Signaling TechnologyTM) according to the manufacturer's protocol.

Techniques:

Journal:

Article Title: Signaling of short- and long-term regulation of intestinal epithelial type 1 Na + /H + exchanger by interferon- γ

doi: 10.1038/sj.bjp.0706167

Figure Lengend Snippet: Effect of EGCG (20 μM), SB 203580 (10 μM) and PKC downregulation (PKC dr; overnight treatment with 100 nM PDBu) on the abundance of STAT1 and phospho-STAT1 in Caco-2 cells treated for 24 h in the absence (vehicle) and presence of IFN-γ (1000 U ml−1).

Article Snippet: Total and phosphorylated STAT1 protein levels in Caco-2 cells exposed to IFN- γ (1000 U ml −1 ) and anisomycin (100 n M ) for 1, 3 and 24 h were analyzed using the PhosphoPlus® Stat1 (Tyr701) antibody kit (Cell Signaling TechnologyTM) according to the manufacturer's protocol.

Techniques: